B
35.11
-1.29 (-3.54%)
| Previous Close | 36.40 |
| Open | 35.98 |
| Volume | 1,191,232 |
| Avg. Volume (3M) | 2,988,345 |
| Market Cap | 6,677,535,744 |
| Price / Sales | 31.21 |
| 52 Weeks Range | |
| Earnings Date | 30 Apr 2025 - 5 May 2025 |
| Profit Margin | -241.44% |
| Operating Margin (TTM) | -3,762.90% |
| Diluted EPS (TTM) | -2.88 |
| Quarterly Revenue Growth (YOY) | 237.10% |
| Current Ratio (MRQ) | 4.67 |
| Operating Cash Flow (TTM) | -520.73 M |
| Levered Free Cash Flow (TTM) | -288.27 M |
| Return on Assets (TTM) | -47.83% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | BridgeBio Pharma, Inc. | Bullish | Bullish |
AIStockmoo Score
2.0
| Analyst Consensus | 5.0 |
| Insider Activity | 1.5 |
| Price Volatility | -0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 2.00 |
|
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 5.41% |
| % Held by Institutions | 91.10% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Kohlberg Kravis Roberts & Co. L.P. | 31 Dec 2024 | 25,260,971 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 95.00 (Cantor Fitzgerald, 170.58%) | Buy |
| Median | 50.00 (42.41%) | |
| Low | 49.00 (Citigroup, 39.56%) | Buy |
| 49.00 (HC Wainwright & Co., 39.56%) | Buy | |
| Average | 57.50 (63.77%) | |
| Total | 6 Buy | |
| Avg. Price @ Call | 35.74 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Redburn Atlantic | 31 Mar 2025 | 50.00 (42.41%) | Buy | 35.11 |
| JP Morgan | 24 Mar 2025 | 50.00 (42.41%) | Buy | 37.22 |
| Cantor Fitzgerald | 21 Feb 2025 | 95.00 (170.58%) | Buy | 36.85 |
| Citigroup | 21 Feb 2025 | 49.00 (39.56%) | Buy | 36.85 |
| Scotiabank | 21 Feb 2025 | 52.00 (48.11%) | Buy | 36.85 |
| 12 Feb 2025 | 49.00 (39.56%) | Buy | 31.95 | |
| HC Wainwright & Co. | 13 Feb 2025 | 49.00 (39.56%) | Buy | 31.56 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| APULI MARICEL | 33.75 | - | 23,660 | 798,525 |
| TRIMARCHI THOMAS | 33.75 | - | 109,100 | 3,682,125 |
| Aggregate Net Quantity | 132,760 | |||
| Aggregate Net Value ($) | 4,480,650 | |||
| Aggregate Avg. Buy ($) | 33.75 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| APULI MARICEL | Officer | 19 Mar 2025 | Acquired (+) | 23,660 | 33.75 | 798,525 |
| TRIMARCHI THOMAS | Officer | 19 Mar 2025 | Acquired (+) | 109,100 | 33.75 | 3,682,125 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |